HILL, E.F., HEATH, R.G., SPANN, J.W., & WILLIAMS, J.D
Additional studies, such as dissolution studies or human plasma exposure can support the safety assessment, e.g., the risk for occlusion of blood vessels is lower if it was demonstrated that particles re-dissolve (Saggu et al., 2021)
Even in the case of prescription, doctors dont recommend long-term treatment
Besides the interleukin family, other genes related to the skin inflammatory mechanism were also upregulated
This is not a stimulant or a short-term fix
As the systematic review noted: No clinical safety data were found. When the FDA says insufficient evidence, they mean itwe literally do not have the data to know whether chronic BPC-157 use causes problems that emerge years down the road